Clinical cancer genomic profiling
D Chakravarty, DB Solit - Nature Reviews Genetics, 2021 - nature.com
Technological innovation and rapid reduction in sequencing costs have enabled the
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …
genomic profiling of hundreds of cancer-associated genes as a component of routine cancer …
Mechanisms and therapeutic implications of hypermutation in gliomas
A high tumour mutational burden (hypermutation) is observed in some gliomas,,,–; however,
the mechanisms by which hypermutation develops and whether it predicts the response to …
the mechanisms by which hypermutation develops and whether it predicts the response to …
[PDF][PDF] Oncogenic signaling pathways in the cancer genome atlas
Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co …
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co …
Genetic and transcriptional evolution alters cancer cell line drug response
Human cancer cell lines are the workhorse of cancer research. Although cell lines are
known to evolve in culture, the extent of the resultant genetic and transcriptional …
known to evolve in culture, the extent of the resultant genetic and transcriptional …
[PDF][PDF] Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of
solid tumors with high tumor mutational burden (TMB-high;≥ 10 variants/Mb). However, the …
solid tumors with high tumor mutational burden (TMB-high;≥ 10 variants/Mb). However, the …
Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib
GR Oxnard, Y Hu, KF Mileham, H Husain… - JAMA …, 2018 - jamanetwork.com
Importance Osimertinib mesylate is used globally to treatEGFR-mutant non–small cell lung
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M …
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M …
Cas9 activates the p53 pathway and selects for p53-inactivating mutations
Cas9 is commonly introduced into cell lines to enable CRISPR–Cas9-mediated genome
editing. Here, we studied the genetic and transcriptional consequences of Cas9 expression …
editing. Here, we studied the genetic and transcriptional consequences of Cas9 expression …
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …
identification of genomic alterations in genes and pathways that can be targeted …
The emerging clinical relevance of genomics in cancer medicine
The combination of next-generation sequencing and advanced computational data analysis
approaches has revolutionized our understanding of the genomic underpinnings of cancer …
approaches has revolutionized our understanding of the genomic underpinnings of cancer …